The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system

Journal of Neuroimmunology

Volumn 107, Issue 2, 2000, Pages 140-147

  Hartung, Hans Peter ^a   Kieseier, Bernd C ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Guillain Barre syndrome; Inflammatory demyelination; Matrix metalloproteinases; Multiple sclerosis

Indexed keywords

MATRIX METALLOPROTEINASE;

ANIMAL CELL; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CYTOKINE RELEASE; DEMYELINATION; EXTRACELLULAR SPACE; GUILLAIN BARRE SYNDROME; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN;

GUILLAIN-BARRE SYNDROME; HUMANS; MATRIX METALLOPROTEINASES; MULTIPLE SCLEROSIS;

EID: 0034710362     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00225-3     Document Type: Conference Paper

References (60)

1. Amberger V.R., Avellane-Adalid V., Mensel T., Baron van Evercooren A., Schwab M.E. European J. Neurosci. 9:1997;151-162.
2. Anthony D.C., Miller K.M., Fearn S., Townsend M.J., Opdenakker G., Wells G.M.A., Clements J.M., Chandler S., Gearing A.J.H., Perry V.H. Matrix metalloproteinase expression in an experimentally induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol. 87:1998;62-72.
3. Arnason B.G.W., Soliven B. Dyck P.J., Thomas P.K., Griffin J.W., Low P.A., Poduslo J. Peripheral Neuropathy. Vol. 3:1993;1437-1497 Saunders, Philadelphia, PA.
4. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7:1995;728-735.
5. Busiek D.F., Baragi V., Nehring L.C., Parks W.C., Welgus H.G. Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J. Immunol. 154:1995;6484-6491.
6. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201:1995;223-226.
7. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C.C., Adams S.E., Gearing A.J.H. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72:1997;155-161.
8. Clements J.M., Cossins J.A., Wells G.M.A., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J.H., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-α inhibitor. J. Neuroimmunol. 74:1997;85-94.
9. Crabbe T., Smith B., O'Connell J., Docherty A. Human progelatinase A can be activated by matrilysin. FEBS Lett. 345:1994;14-16.
10. Cuzner M.L., Davison A.N., Rudge P. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann. Neurol. 4:1978;337-344.
11. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
12. Edwards D.R., Murphy G., Reynolds J.J., Whitham S.E., Docherty A.J., Angel P., Heath J.K. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6:1987;1899-1904.
13. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 277:1997;225-228.
14. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41:1992;29-34.
15. Gijbels K., Proost P., Carton H., Billiau A., Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 36:1993;432-440.
16. Gijbels K., Galardy R.E., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J. Clin. Invest. 94:1994;2177-2182.
17. Hafler D.A., Weiner H.L. MS: a CNS and systemic autoimmune disease. Immunol. Today. 10:1989;104-107.
18. Hartung H.-P., Stoll G., Toyka K.V. Dyck P.J., Thomas P.K., Griffin J.W., Low P.A., Poduslo J. Peripheral Neuropathies. Vol. 3:1993;418-444 Saunders, Philadelphia, PA.
19. Hartung H.-P., Archelos J.J., Zielasek J., Gold R., Koltzenburg M., Reiners K.H., Toyka K.V. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology. 45:(Suppl. 6):1995;S22-32.
20. Hartung H.-P., Willison H., Jung S., Pette M., Toyka K.V., Giegerich G. Autoimmune responses in peripheral nerve. Springer Semin. Immunopathol. 18:1996;97-123.
21. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44:1995;345-349.
22. Hughes P.M., Wells G.M.A., Clements J.M., Gearing A.J.H., Redford E.J., Davies M., Smith K.J., Hughes R.A.C., Brown M.C., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain. 121:1998;481-494.
23. Kieseier B.C., Clements J.M., Pischel H.B., Wells G.M.A., Miller K., Gearing A.J.H., Hartung H.-P. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré Syndrome. Ann. Neurol. 43:1998;427-434.
24. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M.A., Schweitzer T., Gearing A.J.H., Hartung H.-P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 121:1998;159-166.
25. Kieseier B.C., Seifert T., Giovannoni G., Hartung H.-P. Matrix metalloproteinases in inflammatory demyelination. Targets for treatment. Neurology. 53:1999;20-25.
26. Kleiner D.E. Jr., Stetler-Stevenson W.G. Structural biochemistry and activation of matrix metalloproteases. Curr. Opin. Cell Biol. 5:1993;891-897.
27. Krane S.M. Clinical importance of matrix metalloproteinases and their inhibitors. Ann. NY Acad. Sci. 732:1994;1-10.
28. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: a longitudinal clinical and MRI study. Brain. 122:1999;191-197.
29. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:1995;4379-4389.
30. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334.
31. Leppert D., Hughes P., Huber S., Erne B., Grygar C., Said G., Miller K.M., Steck A.J., Probst A., Fuhr P. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology. 53:1999;62-70.
32. Lichtinghagen R., Seifert T., Kracke A., Marckmann S., Wurster U., Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear cells of patients with multiple sclerosis. J. Neuroimmunol. 99:1999;19-26.
33. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J.H., Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:1998;35-46.
34. Lyons J.G., Birkedal-Hansen B., Pierson M.C., Whitelock J.M., Birkedal Hansen H. Interleukin-1 beta and transforming growth factor-alpha/epidermal growth factor induce expression of M(r) 95 000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes. J. Biol. Chem. 268:1993;19143-19151.
35. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.
36. Mariani S.M., Matiba B., Bäumler C., Krammer P.H. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25:1995;2303-2307.
37. Matyszak M.K., Perry V.H. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J. Neuroimmunol. 69:1996;141-149.
38. Murphy G., Willenbrock F., Crabbe T., O'Shea M., Ward R., Atkinson S., O'Connell J., Docherty A. Regulation of matrix metalloproteinase activity. Ann. NY Acad. Sci. 732:1994;31-41.
39. Nagase H., Itoh Y., Binner S. Interaction of α2-macroglobulin with matrix metalloproteinases and its use for identification of their active forms. Ann. NY Acad. Sci. 732:1994;294-302.
40. Ozenci V., Rinaldi L., Teleshova N., Matusevicius D., Kivisakk P., Kouwenhoven M., Link H. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J. Autoimmun. 12:1999;297-303.
41. Overall C.M. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann. NY Acad. Sci. 732:1994;51-64.
42. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152:1998;729-741.
43. Raine C.S. The Dale E. McFarlin Memorial lecture: the immunology of the multiple sclerosis lesion. Ann. Neurol. 36:1994;S61-S72.
44. Raine C.S. Raine C.S., McFarland H.F., Tourtellotte W.W. Multiple Sclerosis: Clinical and Pathogenetic Basis. 1997;151-171 Chapman & Hall, London.
45. Rawlings N.D., Barrett A.J. Barrett A.J. Methods in Enzymology. Proteolytic Enzymes: Aspartic and Metallo Peptidases. Vol. 248:1995;183-228 Academic Press, San Diego, CA.
46. Redford E.J., Smith K.J., Gregson N.A., Davies M., Hughes P., Gearing A.J.H., Miller K., Hughes R.A.C. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain. 120:1997;1895-1905.
47. Ries C., Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe-Seyler. 376:1995;345-355.
48. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 576:1992;203-207.
49. Rosenberg G.A., Dencoff J.E., McGuire P.G., Liotta L.A., Stetler-Stevenson W.A. Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab. Invest. 71:1994;417-422.
50. Rosenberg G.A., Dencoff J.E., Correa N., Reiners M., Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 46:1996;1626-1632.
51. Shapiro S.D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10:1998;602-608.
52. Stetler-Stevenson W.G., Krutzsch H.C., Liotta L.A. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J. Biol. Chem. 264:1989;17374-17378.
53. Takino T., Sato H., Yamamoto E., Seiki M. Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene. 155:1995;293-298.
54. Uhm J.H., Dooley N.P., Lys O.H., Yong V.W. GLIA. 22:1998;53-63.
55. Unemori E.N., Hibbs M.S., Amento E.P. Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. J. Clin. Invest. 88:1991;1656-1662.
56. Utz U., McFarland H.F. The role of T cells in multiple sclerosis: implications for therapies targeting the T cell receptor. J. Neuropathol. Exp. Neurol. 53:1994;351-358.
57. Vassalli J.-D., Pepper M.S. Membrane proteases in focus. Nature. 370:1994;14-15.
58. Wilson C.L., Heppner K.J., Labosky P.A., Hogan B.L., Matrisian L.M. Intestinal tumorgenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA. 94:1997;1402-1407.
59. Woessner J.F. Jr. The family of matrix metalloproteinases. Ann. NY Acad. Sci. 732:1994;11-21.
60. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21:1998;75-80.